Increasing Prevalence of Diabetes and Launch of Integrated Diabetes Solutions to Augment Growth of Insulin Market

 

Insulin Market

Insulin is a soluble, polysaccharide glycan hormone produced by pancreatic beta cells in the pancreas; it is presently considered the most important hormones of the human body. It controls the metabolism of protein, fats, and carbohydrates by stimulating the absorption of glucose in the bloodstream into fat, liver and muscle tissues. It also stimulates the utilization of proteins for energy production in the cells and helps in the storage of glycogen, a glucose-energy reserve in the liver and muscles. Glycogen is responsible for storing glucose and other nutrients during physical exercise. The release of insulin in the bloodstream causes stimulation of carbohydrate metabolism in the liver, resulting in low blood glucose levels.

Market Dynamics

Increasing prevalence of diabetes is expected to propel growth of the global insulin market. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.   

Launch of integrated diabetes solutions is expected to offer lucrative growth opportunities for players in the global insulin market. For instance, in October 2019, Tandem Diabetes Care Inc. partnered with Abbott to develop and commercialize integrated diabetes solutions that combine Abbott's glucose sensing technology with Tandem's insulin delivery systems. Moreover, availability of treatment options for insulin resistance is also expected to aid in growth of the market. For instance, in December 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced an agreement whereby Tonix has acquired the exclusive license to the University of Geneva’s technology for using oxytocin to treat insulin resistance and related syndromes, including obesity, from privately held Katana Pharmaceuticals, Inc.

Competitive Analysis

Major players operating in the global insulin market include, Eli Lilly and Company, Novo Nordisk A/ S, Julphar Gulf Pharmaceutical Industries, Arecor Limited, Sanofi S.A., Biocon Limited, GlaxoSmithKline, and Wockhardt.

Major players operating in the global insulin market are focused on R&D to expand their product portfolio. For instance, in December 2020, Arecor Limited announced dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

Pressure Bandages Market : Global Industry Analysis and Opportunity Assessment

Botanical and Plant Derived Drugs Market by Source,Dosage - Global Industry Analysis,Size,Share